Spanish Agency for Medicines and Health Products (Emps) released this Tuesday a new batch of Treatment Positioning Report (IPT). There were ten reports of the drug being used to treat conditions such as diabetes, hair loss and cancer.
Specifically, reports have been presented for the treatment of multiple myeloma, gastric adenocarcinomaneurofibromatosis, chronic myelogenous leukemiaolestasis, diabetes, pneumonia and COVID-19.
For the treatment of multiple myeloma, Health has released two IPTs. which analyzed idecabtagene vicleucel (abekema) for relapsed and refractory multiple myeloma. In detail, it is an advanced treatment drug, “gene therapy” Contains T lymphocytes extracted from patients for immunotherapy“. This BMS product has received FDA approval as the first T-cell immunotherapy targeting B lymphocyte maturation antigen (BCMA). Along the same lines, it has been analyzed Ciltacabtagene autoleucel (kavicti), Janssen also targets the same patient situation.
Another published document concerns odevixibat (Byrway), author: Yi Psen, in progressive familial intrahepatic cholestasis, for patients who have been treating the disease for at least six months. It is also indicated for the treatment of cholestatic pruritus in a 6-month-old patient with Alaghier syndrome, “the subject of another IPT,” detailed.
There are also reports of trastuzumab deruxtecan (enkhtu), an outcome of the alliance between Daiichi Sankyo and AstraZeneca, in monotherapy HER2 adenocarcinoma of the stomach or gastroesophageal junction Late-stage positive patients previously treated with trastuzumab. According to the publication, the drug comes as a concentrated powder in 100-mg vials for infusion solution.
Other drug analysis
Regarding neurofibromatosis, the Ministry of Health announced the IPT for selumetinib (koselugo), author: Alexsion.Specifically, in April 2021, the Committee for Medicinal Products for Human Use took a positive opinion and therefore recommended the grant of conditional marketing authorization aimed atl Treatment of pediatric patients Symptomatic, inoperable plexiform neurofibromas (PN) in patients with neurofibromatosis type 1 for more than three years.
Asciminib has been studied in cases of Philadelphia chromosome-positive (CML-CF Ph+) chronic phase chronic myelogenous leukemia who have been previously treated with two or more tyrosine kinase inhibitors.Senblix). The drug, from Novartis, was approved by the North American agency in 2021 for two indications, one of which was analyzed by the Spanish agency.
Also on the list is the drug tezepatide (Monzaro), Lily, in diabetes Type 2; baricitinib (Olumit), from Eli Lilly and Company, for the treatment of severe alopecia areata; delafloxacin (Kofinix), Menarini in community-acquired pneumonia (CAP); Casirivimab/imdevimab (Rhone Preve), from Roche, for the treatment and prevention of SARS-CoV-2 infection
Although it may contain statements, data, or notes from health agencies or professionals, the information contained in medical writing is compiled and prepared by journalists. Readers are advised to consult a healthcare professional with any health-related questions.